| |
 |
 |
| |
| Contact Information |
Phone:
913-238-1144
Email:
emgallupmd@aol.com
Address:
236 Arapaho E
Lake Quivira, KS 66217
United States
|
|
|
Elizabeth Gallup
CEO and Founder
Elizabeth Gallup, M.D., JD, MBA, CCTI
Mississippi's Forgotten
CEO and Founder
Mississippi's Forgotten
236 Arapaho E. Circle
Lake Quivira, KS
CURRENT POSITION:
President, Hearts with Hands ElderCare Physicians, Lake Quivira, KS
Medical Director for KS and MO, Vitas Hospice
Medical Director, John Knox Village Care Center, Lee's Summit, MO
Medical Director, Riverside Nursing and Rehabilitation Center, Riverside, MO
September 2005 – Present Founder and Medical Director
Mississippi's Forgotten
A medical relief organization
PO Box 23710
Shawnee Mission, KS 66283
September 2006 - May 2007 Medical Director -
Mission Medical Group of
Kansas and Missouri
August 2003 – January 2006 President – Founder
Medical Strategies, Inc.
5799 Broadmoor, Suite 104
Mission, Kansas 66202
January 1999 – Present President, Medical Director, Founder
New Century Health Quality Alliance, Inc.
5799 Broadmoor, Suite 104
Mission, Kansas 66202
EDUCATION:
1997 MBA
University of Florida
Tampa, FL
1986 JD
University of Toledo, College of Law
Toledo, OH
1981 MD
Ohio State University
College of Medicine
Columbus Ohio
1977 BS
University of Toledo
Toledo, OH
POSTGRADUATE TRAINING:
July 1982 – June 1984 Residency, Family Practice
Flower Hospital
Sylvania, OH
July 1981 – June 1982 Internship, Flexible
Medical College of Ohio
Toledo, OH
LICENSES:
Valid to 11/8/05 ACRP – Certified Clinical Trial Investigator
Valid to 6/30/06 Medicine & Surgery – Kansas, License # 04-22635
Valid to 1/31/06 Physician & Surgeon – Missouri, License # R2K23
Valid to 9/30/07 DEA - Certificate # BG7309330
BOARD CERTIFICATIONS:
1984 -1990, 1991-1997, Recertification, American Board of Family Practice
1998-2004, 2005 - 2011
2004 American Association of Urgent Care Medicine
PAST POSITIONS:
March 2004 – October 2004 Medical Director
Radiant Research - Heartland Primary Care
Kansas City, Kansas
October 2003 – October 2004 Medical Director
Radiant Research, Kansas City
12200 W. 106th, Suite 330
Overland Park, Kansas 66215
December 2003 – June 2004 Regional Medical Director
Liberty Mutual Assurance Company
Mission, KS
February 2000 – Sept 2003 Associate Medical Director
Radiant Research, Kansas City
12200 W. 106th, Suite 330
Overland Park, Kansas 66215
May 2000 – December 2003 Consulting Physician
Liberty Mutual Assurance Company
Mission, KS
December 1998 – August 2003 Executive Director
North American Medical Management
Mission, KS
July 1996 – December 1998 Co-Founder, President
STRATICS – Combining Strategy and Tactics
Management Company
Overland Park, KS
January 1993 – July 1996 Sr. Vice President – Business Development
Shawnee Mission Medical Center
Shawnee Mission, KS
January 1992 – December 1992 Associate
William M. Mercer
Kansas City, MO
June 1991 – December 1991 Global Medical Director
Trans World Airlines
Kansas City, MO
July 1989 – June 1991 Associate General Counsel
American Academy of Family Physicians
Kansas City, MO
July 1984 – June 1989 Family Practitioner
The Defiance Clinic
Defiance, OH
PROFESSIONAL ORGANIZATIONS:
Member, Association of Clinical Research Professionals
Founding member, American Medical Society for Sports Medicine
Fellow, American College of Legal Medicine
Member, National Association of Managed Care Physicians
Member, American College of Physician Executives
Member, American Medical Association
Member, Kansas Medical Association
APPOINTMENTS:
2001 – 2004 Radiant Research Medical Advisory Board
1987 – 1995 Associate Professor, Family Medicine
University of Missouri – Kansas City
1984 – 1989 Adjunct Professor, The Defiance College
AWARDS AND HONORS:
2004 Top 25 Women Who Mean Business, Kansas City Business Journal
1995 Emerging Leader in Healthcare, The Healthcare Forum and Korn/Ferry International
1984 Outstanding Young Women in America
1984 Outstanding Young Women in Defiance, Ohio
1982 Ohio Academy of Family Physician Resident State Delegate to Ohio
Convention
Undergraduate Education – Phi Kappa Phi Honorary, Phi Eta Sigma Honorary, Pre-Med Honorary
Medical School – Honors – Family Medicine, Internal Medicine x2; Commendations – Community Medicine, Family Medicine, Obstetrics, Pediatrics and Psychiatry
PUBLICATIONS:
Books:
1. Gallup, Elizabeth M., Slayton, Cyd R., How Physicians Can Avoid Surrender and Lead Change, American College of Physician Executives, 1997
2. Gallup, Elizabeth M., Law and the Team Physician, Human Kinetics Press, 1994
3. Gallup, Elizabeth M., The Wellness Way to Weight Loss, Plenum Press, New York and London, 1990
Chapters:
1. Gallup, Elizabeth M., Chapter entitled "Sports Medicine and the Law." Mellion, Morris B., Sports Medicine Secrets, Hanley & Belfus, Inc., 1994 updated 1997
2. Gallup, Elizabeth M., Chapter entitled “Organizational and Operational Concerns.” Michael R. Callahan, Andrew J. Demetriou, Thomas E. Dutton, Co-Chairs, Combinations and Alliances in the Health Care Industry, Prentice Hall Law & Business, 1994
3. Gallup, Elizabeth M., Chapter entitled "Medicolegal Issues of Sports Medicine,” Current Review of Sports Medicine, 1993
4. Gallup, Elizabeth M., Chapter entitled "Legal Aspects of Exercise Prescription in Pregnancy." Artal, R., Wiswell, R., Drinkwater, B., Exercise in Pregnancy, Second Edition, 1990
Columns:
1. Monthly Column for “Physicians and Managed Care” Published by American Health Consultants, Atlanta GA
2. “Pros and Cons of Contact Cap vs. PMPM” October 1998
3. “Reasons to consider an IPA”; “Points to consider when signing an IPA contract”, September1998
4. “The importance of patient “chitchat”, August 1998
5. “E/M delay is a wake-up call for physicians”; “ Why capitation requires collaboration”, June 1998
6. “Why it’s essential to embrace Alternative Care”; “Should you jump on the PSO bandwagon?” May 1998
7. “Academic Medical Centers: Down, but not out”, April 1998
8. “How to handle late payments”; “Understanding how MCOs judge practices”, March 1998
9. “Take control of your relationships with MCOs”, February 1998
10. "IDS--Why Should Physicians Participate?"--Physician Capitation Survival (a medical economics newsletter), 1995
11. Monthly Column on Wellness for national magazine, "Women Today." 1987
12. Ohio Family Physicians News--Column on legal implications of medical practice, 1985-1989
13. Ohio Family Physicians New Legislative Update Column (monthly column delineating legislation pending before Ohio Congress), 1985-1989
Articles:
1. Gallup, Elizabeth M. et al, “A Multicenter, Open-Label Study to Assess the Safety and Efficacy of Ciclopirox Topical Suspension 0.77% in the Treatment of Diaper Dermatitis Due to Candida Albicans”; Journal of Drugs in Dermatology; New Methods and Techniques, January/February 2005, Vol. 4, Issue 1
2. Gallup, Elizabeth M., “Coverage Inequalities of New Therapies for Rheumatoid Arthritis in a Managed Care Setting,” Managed Care Interface, July 2001
3. Gallup, Elizabeth M., Dujovne, Carlos A., “New Pharmacological Agents Under Clinical Investigation for Treating Disorders of Lipoprotein Regulation Leading to Atherosclerosis,” Exp. Opin. Invest. Drugs, 2001
4. Gallup, Elizabeth M., “AIDS, Athletes, and Liability,” Sports Medicine in Primary Care, May 1995
5. Gallup, Elizabeth M., "Death on the Court: A look at the tragic death of NBA star Reggie Lewis, " The Sports Medicine Standards and Malpractice Reporter, January 1994
6. Gallup, Elizabeth M., "Staying Inbound and Out of Court" Physicians and Sports Medicine Journal, 1991
7. Gallup, Elizabeth M., Gordon Schmittling, M.S., "Professional Liability Insurance and Moonlighting: Issues & Concerns in the Family Practice Residency Program," The Journal of Family Practice, October 1991
8. Gallup, Elizabeth M., "Treatment of Thigh Contusions to Athletes," Unpublished
9. Gallup, Elizabeth M., "Benign Parotid Enlargement in Bulimia" Submitted and published in Annals of Internal Medicine, December 1980
PRESENTATIONS:
2004
1. “Cancer Support Networks” Northwestern Ohio Cancer Support Group
2. “HIPAA and Employer Sponsored Health Plans” The Hay Group, Kansas City, MO
3. “Liberty Mutual Disability Support” Liberty Mutual, Phoenix, Arizona
4. “Liberty Mutual Disability Support” Liberty Mutual, Kansas City, MO
5. “Evaluation of Headache” Liberty Mutual, Kansas City, MO
6. “Multiple Sclerosis” Liberty Mutual, Kansas City, MO
7. “Carpal Tunnel Syndrome” Liberty Mutual, Kansas City, MO
2003
1. “HIPAA and Research” Radiant Research All Site Meeting, Phoenix Arizona
2. “Heart Failure” Liberty Mutual, Kansas City, MO
3. “Psoriasis” Liberty Mutual, Kansas City, MO
2002
1. “HIPAA and Research” Radiant Research All Site Meeting, Phoenix Arizona
2000
1. “Strategies & Referral Guidelines for Primary Care,” Dover Communications, Las Vegas, NV
2. “Lovenox® Use as Prophylaxis in Managed Care,” Rhône-Poulenc Rorer, Inc., Tucson, AZ
1999
1. “Review Current Health Plan Requirements Regarding: Formulary Inclusion, Pharmacoeconomics, Value Added Services and Partnership Opportunities,” National Managed Care Advisory Board, Rhône-Poulenc Rorer, Inc., Chicago, IL
2. “Medicine and Managed Care—Issues for Physicians and Patients,” Kansas City Rotary, Overland Park, KS
3. “The State of Medicine in Kansas City,” Donnelly, Meiners, Jordan & Kline, Kansas City, MO
4. “Use of Enbrel for RA in Managed Care Setting,” Dover Communications, San Francisco, CA
5. “Strategic Implications,” Lovenox® Core Curriculum Development Meeting, Rhône-Poulenc Rorer, Inc., Philadelphia, PA
6. “Women In Medicine,” University Missouri Kansas City Medical School, Kansas City, MO
7. “Use of Enbrel for RA in Managed Care Setting,” Dover Communications, Nantucket
8. “Use of Enbrel for RA in Managed Care Setting,” Dover Communications, Los Angeles, CA
9. “Managed Care Can Be Good,” Nationwide commercial spots—Council for Health Care Quality, Los Angeles, CA
1998
1. “The Future of Health Care from the Perspective of the Physician”, Zeneca Pharmaceuticals, Cape Cod, Mass.
2. “The Future of Physician Groups”, Pinsonault Associates, Dana Point, CA
3. “Developing an MSO” Health Management Services Association, Blue Cross & Blue Shield, Honolulu, Hawaii
4. “Developing a PSO” Phone Poulenc Rorer-PSO Summit, Phoenix Arizona
1997
1. “Managed Care – The 90’s And Beyond,” Physician’s Health Plan, Phoenix, AZ,
2. “A Report Card on Report Cards: HEDIS/NCQA,” The National Association of Managed Care Physicians, Ft. Myers, FL,
3. “Physician and Capitation”-St Joseph PHO Presentation, Dallas, TX.
4. “Capitation & Quality,” National Managed Health Care Congress, Atlanta, GA,
5. “Progress in Practice,” Carlson HealthCare Publications, Naples, FL,
6. “NCQA & HEDIS 3.0 Update,” National Association if Managed Care Physicians, Colonial Williamsburg, VA,
7. “Richmond Tutorial in Managed Care-Developing Physician Organizations,” American College of Managed Care Medicine, Glen Allen, VA,
8. “Master Contract Liability - Keeping the Lawyer as Your Patient and Out of the Courtroom,” CAPCON, Palm Beach Gardens, FL,
1996
1. “Integrated Delivery Systems,” Chillicothe Memorial Hospital Medical Staff, Chillicothe, OH,
2. “Integration and Collaboration, Physicians and Integration: A Rural Perspective,” Rural Healthcare Leadership Conference, Scottsdale, AZ,
1995
1. “Quality Care,” The National Association of Managed Care Physicians Fall Forum, Norfolk, VA,
2. “The Marriage of Medicine and Management,” Peace Health Leadership Retreat, Bend, OR,
3. "Schizophrenia of the Obstetrician/Gynecologist in a Capitated Environment", to OB/GYN Chairs of the state of New York, Syracuse, NY,
4. “Physicians: Integration and Managed Care, Challenges and Opportunities”, Greater Kansas City Society of Hospital Attorneys, Kansas City, MO,
5. “Practical Considerations in Sports Medicine and the Law,” The Sport Foundation, Palm Springs, CA,
6. "The Development of Integrated Systems: To Be In, To Be Out, To Be Without", Mercy Hospital medical staff and hospital trustees, Iowa City, Iowa,
7. "Integrated Delivery Systems: Past, Present, and Future, The Role of Primary Care vs. Specialist Physicians", The Department of Obstetrics and Gynecology and the Fertility Society of Upstate New York,
8. "Schizophrenia of the Obstetrician/Gynecologist in a Capitated Environment", Obstetrics and Gynecology Grand Rounds SUNY Health Science Center, Syracuse, New York,
9. “Managed Care--The 90’s and Beyond: Formulary Issues,” U.S. Army Office of Continuing Medical Education, Ft. Leonard Wood, MO,
1994
1. "Physician Compensation in a PHO," PHO development meeting of the Michigan State Medical Society,
2. "Risk Sharing Models in PHOs," American Association of PHOs,
3. "How to Select, Evaluate and Manage Your Consultant," presenting with Julie Quirin as keynote speakers to the annual meeting of the National Association of PHOs,
4. "The Shape of Health Care Delivery System of the Future", Family Practice Residents,
5. "Healthcare Alphabet Soup", Shawnee Chamber of Commerce,
6. Breathing Life Into An Integrated Delivery System", Premier Health Alliance, Hershey, PA,
7. "How to Avoid Conflicts in a Capitated Environment", Infoline Seminars,
8. "Developing a Business Plan", The Lower Cape Fear IPA,
9. "Integrated Delivery Systems, The Ball's In Your Court", Kansas City Health Care Summit,
1993
1. "How to Create Physician Directed/Sensitive PHOs", American Association of Managed Care Physicians,
2. "How to Survive in the Competitive Era of Healthcare Reform", group of insurance company executives,
3. "How to Anticipate and Participate in Healthcare Reform", grand rounds talks,
4. "Developing Integrated Delivery Systems", Kansas City chapter of Healthcare Executives,
5. "Healthcare Reform", Kansas City area business executives
Poster Presentations:
Gallup, Elizabeth et al “Low Density Lipoprotein Lowering Efficacy of the Ezetimibe / Simvastatin Combination Tablet In A Large Cohort Of Women”; Second International Conference on Women, Heart Disease, and Stroke; Orlando, Florida, February 2005
TELEVISION APPEARANCES:
· McNeil Lehr Report – Managed Care Debate, November, 2000
· WDAF Channel Forum – Weekly Noon New Appearances, “Wednesday Wellness Doctor”, January 2000 – July 2003
RESEARCH:
1. Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naive Subjects with Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated with Insulin XXX or XXX Insulin.
2. A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group, Study of the Safety and Efficacy of XXX in Combination with XXX Compared to XXX Alone, XXX Alone and Placebo in a Population of Type 2 Diabetic Men and Women.
3. A Double-Blind Comparison of 10, 20, 40 and 80 mg Doses of a Modified-Release Formulation of XXX, of XXX 10 mg, and of XXX 20 mg with Placebo in Hypercholesterolemic Subjects.
4. A Double-Blind Randomized Study to Evaluate the Effects of Fixed Combination XXX/XXX Therapy in Subjects with Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control on Half-Maximum to Maximum of the Labeled Doses of Sulfonylurea Monotheraphy.
5. A Multicenter, Randomized, Double-Blind Clinical Trial Comparing the Safety and Efficacy of XXX/XXX Tablets to XXX Plus XXX Therapy in Patients with Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control with Metformin Monotherapy.
6. A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Multidose Study to Evaluate the Efficacy and Safety of Subcutaneously Administered XXX in Adults with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy.
7. A 6-Month Multicenter, Randomized, Double-Blind, Pilot Study to Investigate the Tolerability and Efficacy of XXX Compared to Placebo for the Treatment of Mild Depressive Symptoms and Obesity.
8. A Randomized, Multicenter, Double-Blind, Parallel-Group Clinical Study to Compare the Effects of XXX Versus Placebo as Initial Oral Therapy in Subjects with Type 2 Diabetes Mellitus who Fail to Achieve Adequate Glycemic Control with Diet and Exercise Alone.
9. A Randomized, Multi-Center, Double Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study of the Safety and Efficacy of XXX in Patients with Mild Thyroid Failure.
10. Phase IIb Study of XXX 25 and 50 mg/day Conventional Tablet vs. XXX in Patients with Hypercholesterolemia.
11. A Multicenter, Double-Blind, Randomized, Parallel, 28-Week Study to Evaluate the Efficacy and Safety of XXX 80mg/day Versus XXX 80mg/day in Patients with Hypercholesterolemia
12. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, “Factorial” Design, 48-Week Extension Study to Evaluate the Safety of XXX 10mg/day Co-administered with Multiple Doses of XXX in Patients with Primary Hypercholesterolemia.
13. Long-Term, Safety and Tolerability Study of XXX or Placebo in Addition to XXX in Subjects with Primary Hypercholesterolemia.
14. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of XXX when Added to Ongoing Therapy with an HMG-CoA Reductase Inhibitor (Statin) in Patients with Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors.
15. A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Active-Controlled Trial in Patients with Essential Hypertension to Compare the Effect of XXX 80 and 160 mg, with or without the Addition of XXX, Once Daily to that of XXX 5 and 10 mg Once Daily, with or without the Addition of XXX, or Cardiovascular Morbidity and Mortality.
16. Phase 2 Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Dose Ranging Study of the Safety, Efficacy and Tolerability of XXX Soft-Gel Capsules Administered Orally to Subjects with a Low Level of High Density Lipoprotein Cholesterol.
17. Phase 2 Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Dose Ranging Study of the Safety, Efficacy and Tolerability of XXX Soft-Gel Capsules Administered Orally to Subjects with a Low Level of High Density Lipoprotein Cholesterol Receiving XXX 20 MG/Day
18. Phase 2 Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Single Dose Study of the Safety, Efficacy and Tolerability of XXX Soft-Gel Capsules Administered Orally to Subjects with or without Low Levels of High Density Lipoprotein Cholesterol.
19. A 1-Year, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of XXX in Patients with Effort-Induced Chronic Stable Angina.
20. A 1-Year Double-Blind Extension Study to Protocol XXX: A 1-Year Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of XXX in Patients with Effort-Induced Chronic Stable Angina.
21. A 16-Week, Double-Blind, Multicenter Study to Evaluate the Effect of XXX in Combination with XXX on Lipids in Patients with Type IIa and IIb Dyslipidemia.
22. A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of XXX in Patients with Low HDL-C and Either Normal or Elevated Triglycerides.
23. The Safety and Efficacy of XXX Versus XXX: A One-Year, Randomized, Double-Blind, Parallel Group, Active Comparator Study.
24. Clinical Protocol for a Randomized, Double-Blind, Placebo-Controlled Study of XXX as Monotheraphy in Patients with Primary Hypercholesterolemia.
25. A Single Dose, Double-Blind, Safety and Efficacy Study of XXX. XXX and XXX Sodium in Subjects with Acute Migraine Attacks.
26. A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Evaluation of XXX and XXX Alone and in Combination, in the Acute Treatment of a Migraine Attack.
27. A Double-Blind Randomized Comparison of the Efficacy and Safety of 52 weeks of XXX Therapy plus diet in the Treatment of Obesity in Peri- and Post-Menopausal Women at Cardiovascular Risk followed by 52 weeks Open Label Treatment with XXX to Evaluate maintenance of Weight Loss.
28. A Double - Blind, Placebo-Controlled, Randomized, Dose-Ranging Study of XXX as Monotherapy and in Combination Therapy with XXX.
29. A Randomized, Double-blind, Placebo-controlled Parallel Group, 6-Week Evaluation of XXX 0.4 mg and XXX 10 mg in Post-Menopausal Women with Hyperlipidemia and a 46-Week Evaluation in which XXX 0.4 mg is Compared to XXX 201 mg for Long-term Lipid-lowering and Bone Mineral Density Effects.
30. A phase III Multi-Center, Three-Arm Study to Assess the Efficacy and Safety of XXX in the Management of Obesity.
31. A phase III Double-Blind Efficacy and Safety Study on one Dose of XXX (10mg) Compared to Placebo in Subjects with Primary Hypercholesterolemia.
32. A Long-Term, Open Label, Safety and Tolerability Study of XXX in Subjects with Primary Hypercholesterolemia.
33. A Phase III Double-Blind Efficacy and Safety Study of XXX (10mg) in addition to XXX Compared to Placebo in Subjects with Primary Hypercholesterolemia.
34. A Phase III Double-Blind Efficacy and Safety Study of XXX (10mg) in addition to XXX in Subjects with Coronary Heart Disease or Multiple Cardiovascular Risk Factors and with Primary Hypercholesterolemia not Controlled by a Starting Dose (10mg) of XXX.
35. Phase II, Dose-Response Effects of XXX on Lipoproteins in Subjects with Decreased HDL-C Levels.
36. Phase II, Dose-Response Study of XXX in Subjects with Marked Hypertriglyceridemia.
37. An Open-label, Multinational, Multicenter, Extension Trial to Assess the Long-term Safety and Efficacy of XXX in Subjects in the XXX Clinical Trial Program.
38. A Double - Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Three Doses of XXX in Obese Patients.
39. A Randomized, Double - Blind, Multicenter Trial to Compare the Short-term and Long-term Efficacy and Safety of XXX, XXX, and XXX in the Treatment of Subjects with Hypercholesterolemia.
40. A Randomized, Double - Blind, Placebo-Controlled Trial of Once per Day Versus Split Dosing of XXX in Patients with Primary Hypercholesterolemia.
41. An Open-Label, Randomized Study of the Relative Efficacy of XXX Compared to XXX and XXX.
42. A Multicenter, Double-Blind, Randomized, Placebo -and- Active-Comparator—Controlled, Parallel Study to Evaluate the Glucose-Lowering Efficacy, Lipid-Altering Efficacy, Safety, and Tolerability of XXX in Patients with Type 2 Diabetes.
43. A Multicenter, Double - Blind, Randomized, Placebo – and Active –Comparator-Controlled, Parallel Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of XXX in Patients with Mixed Hyperlipidemia.
44. A Double Blind, Placebo Controlled, Multi-Center Study to Assess the Effects of Extended Treatment and Re-Treatment in Patients with Plaque Psoriasis Enrolled in XXX Part 2.
45. A Two-Part, Multi-Center, Randomized, Double - Blind, Placebo-Controlled, Multiple Dose Clinical Trial of XXX in Patients with Moderate to Severe Plaque Psoriasis.
46. A Randomized, Double Blind, Placebo-Controlled, Crossover Study of Oral XXX in Adults with Lipid Disorders.
47. A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered XXX in Adults With Moderate to Severe Plaque Psoriasis.
48. An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered XXX Followed by XXX Taper in Adults With Plaque Psoriasis Previously Enrolled in Study XXX.
49. A Comparison of Treatment With XXX and XXX Coadministration Versus XXX in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-C) Target Level.
50. A Multicenter, Double - Blind, Randomized, Placebo-and Active-Controlled, Parallel Study to Evaluate the Glucose and Lipid-Altering Efficacy and Safety of XXX in Patients with Type 2 Diabetes.
51. A Multicenter, Double - Blind, Randomized, Placebo-and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy and Safety of XXX in Patients with Metabolic Syndrome and Dyslipidemia.
52. Phase 2 Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Dose Ranging Study of the Safety, Efficacy and Tolerability of an Oral Formulation of XXX Administered BID for 8 Weeks to Subjects with Moderate Elevations in Low-Density Lipoprotein Cholesterol Levels and Without Overt Cardiovascular Disease.
53. Phase 2 Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Dose Ranging Study of the Safety, Efficacy and Tolerability of an Oral Formulation of XXX Administered BID on a Background of XXX 20 mg/ day for 8 Weeks to Subjects with Elevated Low-Density Lipoprotein Cholesterol and Without Overt Cardiovascular Disease.
54. A Phase III, 12-Month, Double Blind, Randomized, Parallel Group, Placebo Controlled, Efficacy and Safety Study of XXX in Overweight and Obese Subjects With a 12-Month Open-Label Extension Phase.
55. A 6-week, Open-Label, Dose-comparison Study to Evaluate the Safety and Efficacy of XXX Versus XXX, XXX, XXX, and XXX in Subjects With Hypercholesterolemia.
56. A Phase I/II, Randomized, Double Blind, Dose-Ranging, Placebo-Controlled, Pharmacokinetic Study of the Safety and Activity of XXX Administered by the Buccal Route in Patients With Metabolic Syndrome.
57. A Multicenter, Double - Blind, Randomized, Parallel Study Comparing the Efficacy and Safety of XXX 120 MG BID, XXX 240 MG QD and Placebo in Subjects with Perennial Allergic Rhinitis.
58. A Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel Group 6-week Treatment Study Comparing XXX combined with XXX (50 mg/12.5 mg) Tablets using Ambulatory Blood Pressure Monitoring in Patients with Mild-to-Moderate Hypertension.
59. A Multicenter, Randomized, Double-blind, Placebo-and-Active-controlled Parallel Group Dose-ranging Study of the HMG CoA Reductase Inhibitor, XXX, in the Treatment of Hyperlipidemia
60. A Double-Blind, Randomized, Multicenter, Parallel Dose Study to Evaluate the Safety and Efficacy of XXX 150mg and 300mg per Day and Placebo in Subjects with Migraine Headache.
61. A Dose Range-Finding, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of XXX in Obese Subjects
62. A Comparison of Treatment With XXX and XXX Coadministration Versus XXX in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-C) Target Level.
63. A Multicenter, Randomized, Double - Blind, Placebo-Controlled, “Factorial” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of XXX/XXX Combination Tablet in Patients with Primary Hypercholesterolemia.
64. A Randomized, Double - Blind, Multi-Center Study to Asses the Safety of Long-Term Administration of Two Dose Levels of XXX in Patients with Primary Insomnia.
65. Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study of the Safety, Efficacy and Tolerability of XXX Administered Orally for 8 Weeks to Subjects with Type 2 Diabetes Mellitus.
66. Phase 2 multi-center, double-blind (XXX), placebo-controlled, randomized, parallel group, dose ranging study of the efficacy, safety, tolerability and pharmacokinetics of XXX and open-label XXX when concurrently administered orally once daily (QD) for 12 weeks to subjects with elevated low-density lipoprotein cholesterol and without overt cardiovascular disease.
67. Phase 2 multi-center, double-blind (XXX), placebo-controlled, randomized, parallel group, dose ranging study of the efficacy, safety, tolerability, and pharmacokinetics of XXX and open-label XXX when concurrently administered orally twice daily (BID) for 12 weeks to subjects with elevated low-density lipoprotein cholesterol and without overt cardiovascular disease.
68. A Phase III Multi-center, Randomized, Double-blind, Parallel Group Study of XXX 20 mg, XXX 40 mg and Placebo in Patients with Multiple Moderate or Severe Acute Migraine Headaches
69. Open-Label, Long-term, Multicenter Study of Safety and Tolerability of XXX 40-60 mg in the Acute Treatment of Migraine in Adults
70. Clinical Protocol for a Double-Blind, Placebo Controlled, Randomized Two Week Comparison Study of the Efficacy and Tolerability of XXX 10 mg QD and XXX 25 mg QD in Relieving the Signs and Symptoms of Osteoarthritis of the Knee.
71. A Double - Blind, Randomized, Placebo-Controlled, Parallel Group, Short-Term Safety and Efficacy Study of Two Doses of XXX in Overweight and Obese Patients with Type 2 Diabetes Mellitus.
72. A Study to Evaluate the Effect of XXX 30 mg QD Versus XXX 40 mg QD on Healing and Symptom Relief in Subjects with Erosive Esophagitis.
73. XXX in the Treatment of Diabetic Patients with Dyslipidemia Using XXX and/or XXX.
74. A Multi-Center Study to Determine the Exposure of Adult U.S. Smokers to Cigarette Smoke.
75. A Randomized, Double - Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of XXX in Obese Patients with Type 2 Diabetes.
76. A Randomized, Double - Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety of XXX in Obese Patients with or without Comorbidities.
77. A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Efficacy and Efficacy and Safety of XXX in the Treatment of Rapid Ejaculation
78. Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment with XXX (40 mg qd) to XXX (30 mg qd) for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis
79. Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates for Once Daily Treatment with XXX 20 mg and XXX 15 mg for 6 Months in Patients Whose EE Has Been Healed
80. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment with XXX 20 mg and 40 mg to Placebo qd in Patients with Heartburn and Sleep Disturbances Associated with Gastroesophageal Reflux Disease (GERD)
81. A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of XXX 120 MG BID in Subjects with Mild to Moderate Persistent Asthma
82. Evaluation of the Efficacy and Safety of XXX XXX Topical Cream in Patients with Moderate to Severe Facial Atopic Dermatitis: A Phase II Clinical Trial
83. A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of XXX on Allergic Rhinitis in Patients with Seasonal Allergic Rhinitis and Chronic Asthma
84. A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of new oral Formulation XXX in Patients with Onychomycosis of the Toenails
85. The Effects of the Combination of XXX and XXX Compared to XXX Alone in Patients with Mixed Hyperlipidemia
86. A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Short-Term, Efficacy and Safety Study of Two Doses of XXX in Overweight and Obese Patients with Type 2 Diabetes Mellitus
87. An Investigation to Assess the Safety and Efficacy of XXX (XXX 0.77%) Topical Suspension (Lotion) in the Treatment of Diaper Dermatitis due to Candida Albicans
88. Extended Use of XXX Laxative in Constipated Patients
89. An Open Label Study of Chronic XXX Use in Constipated Patients
90. A Dose-Ranging and Safety Study of XXX XXX in Hypertensive Pediatric Subjects 6 to
|
